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Influence of obesity and cardiometabolic makers
on lipoprotein-associated phospholipase A2
(Lp-PLA2) activity in adolescents: the healthy
young cross-sectional study
Isis T da Silva1, Anelise de Souza Timm1 and Nágila RT Damasceno1,2*
Abstract
Background: Lipoprotein-associated phospholipase A2 activity (Lp-PLA2) is a good marker of cardiovascular risk in
adults. It is strongly associated with stroke and many others cardiovascular events. Despite this, the impact of
obesity on this enzyme activity and its relation to biomarkers of cardiovascular disease in adolescents is not very
well investigated. The purpose of this article is to evaluate the influence of obesity and cardiometabolic markers on
Lp-PLA2 activity in adolescents.
Results: This cross-sectional study included 242 adolescents (10–19 years) of both gender. These subjects were
classified in Healthy Weight (n = 77), Overweight (n = 82) and Obese (n = 83) groups. Lipid profile, glucose, insulin,
HDL size, LDL(−) and anti-LDL(−) antibodies were analyzed. The Lp-PLA2 activity was determined by a colorimetric
commercial kit. Body mass index (BMI), waist circumference and body composition were monitored. Food intake
was evaluated using three 24-hour diet recalls. The Lp-PLA2 activity changed in function to high BMI, waist
circumference and fat mass percentage. It was also positively associated with HOMA-IR, glucose, insulin and almost
all variables of lipid profile. Furthermore, it was negatively related to Apo AI (β = −0.137; P = 0.038) and strongly
positively associated with Apo B (β = 0.293; P < 0.001) and with Apo B/Apo AI ratio (β = 0.343; P < 0.001). The better
predictor model for enzyme activity, on multivariate analysis, included Apo B/Apo AI (β = 0.327; P < 0.001), HDL size
(β = −0.326; P < 0.001), WC (β = 0.171; P = 0.006) and glucose (β = 0.119; P = 0.038). Logistic regression analysis
demonstrated that changes in Apo B/Apo AI ratio were associated with a 73.5 times higher risk to elevated Lp-PLA2
activity.
Conclusions: Lp-PLA2 changes in function of obesity, and that it shows important associations with markers of
cardiovascular risk, in particular with waist circumference, glucose, HDL size and Apo B/Apo AI ratio. These results
suggest that Lp-PLA2 activity can be a cardiovascular biomarker in adolescence.
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Background
Obesity is developing very fast in all age groups, but the
growth rate has been much more acute in children and
adolescents [1]. According to the National Center for
Health Statistics (NCHS), obesity increased from 5% to
18.1% among adolescents between 1976–1980 and
2007–2008 [1]. This profile is consistent with the Brazilian
Institute of Geographic and Statistic, which showed that
overweight in Brazilian adolescents increased from 16.7%
(2002–2003) to 21.5% (2008–2009) [2].
The metabolic imbalance in obesity supports inflamma-
tion, insulin resistance and oxidation [3-5]. In adolescents,
these components favor the early occurrence of athero-
sclerosis [6] by the emergence of chronic diseases like dia-
betes and abnormal lipid levels [7,8].
* Correspondence: nagila@usp.br
1Department of Nutrition, School of Public Health, University of Sao Paulo,
Sao Paulo, SP, Brazil
2Faculdade de Saúde Pública, Departamento de Nutrição, Av Dr Arnaldo,
715, 01246-904, São Paulo, SP, Brazil
© 2013 da Silva et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
da Silva et al. Lipids in Health and Disease 2013, 12:19
http://www.lipidworld.com/content/12/1/19
Previously Celik et al. (2009) proposed that the inci-
dence of obesity in adolescence may perhaps to repre-
sent a first step to atherosclerosis in adults [9]. Many
factors can be associated with cardiovascular diseases,
and it is known that Lipoprotein-associated phospholi-
pase A2 (Lp-PLA2) is a possible emerging biomarker
[10]. Lp-PLA2 is an enzyme produced by inflammatory
cells [11], that circulates on plasma linked in high pro-
portion with low density lipoprotein (LDL) (85%) and
less proportion to high density lipoprotein (HDL) (15%)
[12]. Afterward, it was observed that Lp-PLA2 has the
ability to hydrolysis oxidized phospholipids, reducing
their biological activity [13]. However, this event results
on the formation of lysophosphatidylcoline and isopro-
tanes, inflammatory components that participate in the
development of atherosclerotic plaque [14].
Furthermore, it has been observed that Lp-PLA2, in
adults, has association with other cardiovascular risk
markers, such as LDL-C and C-reactive protein [15,16].
A recent review showed that Lp-PLA2 is related to car-
diovascular events in adults, even after adjustment by
Framingham risk score and C protein reactive [17]. Des-
pite these results, the monitoring of Lp-PLA2 in children
and adolescents is sparkly described in literature. In
addition, it is not know if obesity is associated to change
of Lp-PLA2 in adolescents. In this context, the aim
of this article is to evaluate the influence of obesity
and cardiometabolic markers on Lp-PLA2 activity in
adolescents.
Methods
Study subjects
In a cross-sectional study, we evaluated boys and girls
adolescents between ten and nineteen years old [18],
selected from public schools (Sao Paulo, SP, Brazil). From
five public schools, 2746 adolescents were enrolled in this
study. This population was initially invited to participate
in the nutritional screening (body mass index – BMI,
weight/height2). After a preliminary nutritional status clas-
sification, all adolescents with overweight (n = 481), obe-
sity (n = 135) and a randomized sub-sample of healthy
weight (n = 756) adolescents were invited to the second
phase of the study. A total of 261 adolescents completed
all stage of data collection.
The exclusion criteria were smoking, the use of alco-
hol (≥ 30.0 mL of ethanol/day for boys and ≥ 15.0 mL of
etanol/day for girls) [19], the use of lipid-lowering drugs,
the presence of any acute disease, the participation in
other protocols research and pregnancy or breastfeeding.
After an examination of collected data, 19 subjects were
excluded due to the use of lipid-lowering and anti-
inflammatory drugs during the collection.
The adolescents included in this study were distributed
into 3 groups: healthy weight (HW), overweight (OV), and
obese (OB), according to the classification of BMI,
proposed by Cole et al. [20,21] for sex and age. The proto-
col study was approved by the Ethics Committee (School
of Public Health, University of Sao Paulo) and followed
the recommendations of the National Council for Health
on Ethics in Research with Humans. All the parents of the
adolescents signed an informed written consent.
Food Intake
The food intake was evaluated by three 24-hour diet
recalls, collected on non consecutive days, including one
weekend day. The first recall was conducted by a direct
interview and the others by phone interview. Energy
(kcal), carbohydrates (g), lipids (g), proteins (g), satura-
ted fat acid (g), monounsaturated fat acid (g), polyunsa-
turated fat acid (g), oleic acid (g), linoleic acid (g),
linolenic acid (g) and fiber (g) were measured through
the software NutWinW [22]. These data were adjusted by
energy [23,24] and by intra-personal variability [25].
Clinical and biochemical assessments
Height and weight were determined by a stadiometer
(AlturaExata, TBW Brazil, Sao Paulo, SP, Brazil) and by a
digital scale (Control, Plenna, Sao Paulo, SP, Brazil), res-
pectively. Waist circumference (WC) was measured using
a 1 mm precision flexible and inelastic tape (TBW BrazilW,
Sao Paulo, SP, Brazil). Body composition was evaluated by
bioelectric bioympedance technique, using the instrument
tetrapolar BiodynamicsW, model 450 (TBW, São Paulo,
Brazil). Sexual maturation was evaluated according to
Marshall and Tanner [26] and Marshall [27]. The levels of
total cholesterol (TC), HDL-cholesterol (HDL-C), and
triglycerides (TG) were determined by standard methods
(Labtest Diagnóstica, MG, Brazil). The LDL-cholesterol
(LDL-C) levels were calculated by the Friedewald equation
[28]. Similarly, TC/HDL-C, LDL-C/HDL-C, no-HDL-C
and TG/HDL-C ratios were calculated. The apolipo-
proteins AI (Apo AI) and B (Apo B) were evaluated
by commercial kits (RANDOXW, Co, Antrim, United
Kingdom). The concentrations of HDL-C and LDL-C were
normalized by Apo AI and B levels, respectively. Poster-
iorly, the HDL size was measured by Laser-Light-Scattering
method established by Lima and Maranhão [29].
The glucose was determined by an enzymatic and
colorimetric commercial kit (Glicose PAP LiquiformW -
Labtest, MG, Brazil). For insulin levels, the radioimmuno-
assay was applied using the standard method (Human
Insulin-Specific RIA Kit, Linco Research, St Charles, MO,
USA). Following up, the insulin resistance was estimated
by HOMA-IR index (homeostasis model assessment –
insulin resistance), where: HOMA-IR = [fasting insulin
level (μU/mL) × fasting glucose (mmol/L)] / 22.5 [30].
The electronegative low density lipoprotein LDL(−)
was assessed by ELISA using monoclonal antibodies
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(MAb 1A3 and MAb 2C7), according to Damasceno
et al. [31], while the autoantibodies against LDL(−) were
evaluated by ELISA, according to Damasceno et al. [32].
Lp-PLA2 activity in plasma was determined by an en-
zymatic PAF-Acetylhydrolase Assay kit (Cayman Chemi-
cal Company, USA). The analyses were performed in
duplicate, with its results expressed in nmol/min/mL.
Statistical analysis
The statistical analyses were performed using the SPSS
software, version 15.0. Following the evaluation of the data
distribution by Kolmogorov-Smirnov test (P > 0.05),
differences between groups were determined by ANOVA
test (normally data) or Kruskal-Wallis and Mann–Whitney
U-test (not normally distributed data). The χ2 test was
used for comparison of categorical variables and results
were expressed as relative frequencies (%). Initially, there
were performed sexual maturation- and sex-specific
analysis; nonetheless, the groups showed similar profiles.
Therefore, these variables were not accepted as con-
founders. Univariated regression models were applied in
order to determine the effect of anthropometric/body
composition and lipid measures (as explanatory variables)
on Lp-PLA2 activity (as dependent outcome). In order to
explore the ability of the variables that showed association
with Lp-PLA2, additive multivariated regression models
were constructed using the following variables: BMI, WC,
% fat mass, TC, LDL-C, TC/HDL-C, non-HDL-C, Apo AI,
Apo B, Apo B/Apo AI, HDL size, insulin, glucose and
HOMA. Results from regression models are showed as
b-coefficients, R-squared values and P- value.
We have also performed the Odd Ratio (OR) using
logistic regression. Regarding that there is no reference
values previously established for Lp-PLA2, we pro
posed the highest quartile (Q4) of Lp-PLA2 activity
(>15.9 nmol/min/mL) such as cutoff point. Statistical
significance was established for P-value <0.05.
Results
Table 1 shows the characteristics of adolescents included
in the study, according to BMI. The proportion of girls
(HW = 51%, OV = 45% and OB = 52%) were statistically
similar between groups (P = 0.321). While the over-
weight adolescents (13.3 ± 1.9 years) was younger than
both obese and healthy weight adolescents (P = 0.006),
the OB group was marked by high fat mass percentage
(32.2 ± 6.9%) and elevated central obesity (98 ± 16.5 cm),
confirming previous BMI classification. It is worth to
emphasize that food intake was similar between the
groups.
As to the lipid profile, HDL-C was lower in OV and OB
groups in comparison to HW group (P = 0.027; P < 0.001,
respectively), and TG was higher in OB group (P = 0.026).
The TC/HDL-C and TG/HDL-C ratios confirmed this
tendency, where obese adolescents showed higher values
in relation to healthy weight adolescents (P = 0.015).
Regarding the apolipoproteins, they were similar between
groups, except for Apo AI and Apo B/Apo AI ratio, where
the OB group showed lower (P = 0.001) and higher
(P = 0.002) levels, respectively, than HW group (Table 2).
The insulin levels and HOMA-IR were higher in OV
(P = 0.002 and P = 0.011, respectively) and OB groups
(P < 0.001; P < 0.001, respectively) than in HW group. The
similar pattern was observed for LDL(−), where obese and
overweight adolescents showed values statistically higher
than HW group (P = 0.049; P = 0.017, respectively). An
opposite profile was noted for anti-LDL(−) (P = 0.045;
P = 0.010, respectively) (Table 2).
The Figure 1 shows that Lp-PLA2 activity changed in
function to obesity. The negative impact of obesity on
Lp-PLA2 activity was reinforced by tertiles of waist circum-
ference and fat mass percentage. Regarding this profile,
correlations between Lp-PLA2 and % fat mass, WC and
BMI in all groups were analyzed, but it weren’t statistically
Table 1 Characteristic of adolescents and food intake,
according to BMI
HW (n = 77) OV (n = 82) OB (n = 83) P
Boys, n (%) 26 (35.7) 37 (52.6) 31 (44.4) 0.320
Girls, n (%) 51 (64.3) 45 (47.4) 52 (55.6)
Age, year 14.4 (2.2) 13.3 (1.9)* 14.2 (2.6)** 0.006
Sexual Maturation 0.710
Pre-pubertal 4 (5) 7 (9) 6 (7)
Pubertal 73 (95) 75 (92) 77 (93)
BMI, kg/m2 20.3 (2.1) 25.0 (1.9)* 32.4 (5.9)*.** <0.001
WC, cm 69 (5.8) 80.7 (5.7)* 98 (16.5)*.** <0.001
Fat mass,% 19.4 (7.9) 24.5 (6.6)* 32.2 (6.9)*.** <0.001
Lean mass,% 76.1 (13.9) 71.3 (9.8)* 67.0 (7.5)*.** <0.001
Food intake
Energy, kcal 1522 (471) 1446 (438) 1563 (521) 0.620
Carbohydrates, g 211 (20) 212 (19) 207 (27) 0.706
Proteins, g 64 (11) 64 (10) 66 (15) 0.719
Fat, g 50 (8) 51 (6) 51 (7) 0.313
SFA, g 17.7 (3.1) 17.4 (2.8) 17.7 (3.3) 0.480
PUFA, g 8.5 (2.0) 9.2 (2.0) 9.0 (2.7) 0.213
MUFA, g 17.3 (2.8) 17.9 (2.8) 17.7 (3.3) 0.159
Oleic acid, g 9.2 (2.2) 9.9 (1.7) 10.7 (2.8) 0.050
Linoleic acid, g 3.9 (1.0) 4.2 (1.0) 4.0 (1.0) 0.142
Linolenic acid, g 0.4 (0.1) 0.5 (0.1) 0.4 (0.1) 0.079
Fiber, g 11.1 (2.8) 10.7 (2.3) 10.7 (2.8) 0.948
HW, healthy weight; OV, overweight; OB, obese; BMI, body mass index; WC,
waist circumference; SFA, saturated fat acid; PUFA, polyunsaturated fat acid;
MUFA, monounsaturated fat acid.
Continuous variables were described as mean (standard deviation).
Categorical variables were described as sample (n) and percentage (%).
*P < 0.05 vs HW group. **P < 0.05 vs OV group.
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significant, excepted for % fat mass that was negatively
related to Lp-PLA2 in the OV group (r = −0.238 p = 0.033).
Table 3 shows the association between Lp-PLA2 activ-
ity and cardiometabolic parameters. Lp-PLA2 activity
was positively associated with almost all variables of lipid
profile, except HDL-C and TG with which there was not
correlation. Besides, Lp-PLA2 was negatively related to
Apo AI (β = −0.137; P = 0.038) and strongly positively
associated with Apo B (β = 0.293; P < 0.001) and with
Apo B/Apo AI ratio (β = 0.343; P < 0.001). Other
evidences are the positive associations with insulin,
HOMA-IR and glucose. The enzyme activity was also
positively associated with BMI (β = 0.195; P = 0.003), WC
(β = 0.270; P < 0.001), fat mass percentage (β = 0.186;
P = 0.004). These significant associations explained 64.5%
of variability of Lp-PLA2, while the non significant
represented 4.1%.
Given the multiple associations obtained in the
univariated test, we analyzed the better model of
multivariable association in order to understand the
Lp-PLA2 activity in adolescents. The better predictor
model was featured by Apo B/Apo AI (β = 0.327;
P < 0.001)
HDL size (β = −0.326; P < 0.001), WC (β = 0.171;
P = 0.006) and glucose (β = 0.119; P = 0.038) (Table 4).
This model explained 26.3% of variability of Lp-PLA2.
Using logistic regression analysis, we were able to
determine the impact of cardiovascular risk factors on
Lp-PLA2 activity (Table 5). Compared to adolescents
with lower Lp-PLA2 activity (<15.9), those with higher
values (≥15.9) exhibited significant association with TC
(OR 1.012, 95% CI = 1.004-1.020, P = 0.004), LDL-C
(OR 1.012, 95% CI = 1.004-1.020, P = 0.003), HOMA-
IR (OR 1.127, 95% CI = 1.010-1.258, P = 0.032), Apo B
(OR 1.042, 95% CI = 1.020-1.064, P < 0.001), Apo B/
Apo AI (OR 73.53, 95% CI = 8.627-626.665, P < 0.001).
The change in Apo B/Apo AI ratio was related to a
73.5 times higher risk to have a high value of Lp-PLA2
(≥15.9).
Discussion
This study showed that Lp-PLA2 activity in adolescence
is associated with many cardimetabolic parameters. The
factors that had an impact in the activity of the enzyme,
from the most to the least important, were the Apo
B/Apo AI ratio, waist circumference, glucose and HDL
size.
Our results demonstrated the negative effect of obesity
on Lp-PLA2 activity, which were reinforced by waist cir-
cumference and fat mass percentage. Among the an-
thropometric variables the waist circumference was the
most important factor explaining the variation in the
Lp-PLA2 activity. This fact confirms the relevance of the
body fat location. Interestingly, analysis of correlations
in individual groups did not show association with
healthy weight and overweight adolescents, except for
fat mass percentage and Lp-PLA2 activity. In this sense,
Taylor and Hergenroeder demonstrated that elevated
waist circumference in male adolescents was associated
with an increased risk of cardiometabolic disease and
overweight females with elevated waist circumference
were likely to have elevated blood pressure [33].
In addition, we demonstrated for the first time the
strong impact of Apo B/Apo AI ratio on changes in Lp-
PLA2 activity; more specifically, the changes in these
apolipoproteins were associated with a 73.5 times higher
risk of elevated Lp-PLA2 activity. Recently, Hatoum
et al. [34], studying patients between 50 and 60 years
old, observed that the enzyme was modestly associated
with total cholesterol, LDL-C, Apo B and BMI; however,
the lipid adjustment attenuates the relation between
BMI and Lp-PLA2. The atherogenic role of Lp-PLA2
was widely associated to LDL-C [16,35]. On the con-
trary, Okamura et al. [16] suggested that Lp-PLA2 in
HDL plays an antiaterogenic action. This observation
was reinforced by a high LDL-Lp-PLA2 to HDL-Lp
-PLA2 ratio verified in patients with atrial fibrillation. In
Table 2 Adolescent’s biochemical profile, according to
BMI
HW (n = 77) OV (n = 82) OB (n = 83) P
TC, mg/dL 143 (32.1) 140 (34.3) 142 (39.8) 0.864
LDL-C, mg/dL 86 (33.5) 85 (35.6) 89 (40.1) 0.800
HDL-C, mg/dL 42 (13.5) 37 (13.3)* 35 (12.6)* <0.001
TG, mg/dL 75 (29.7) 87 (49.7) 91 (45.1)* 0.07
TG/HDL-C 1.90 (0.86) 2.69 (1.98)* 3.07 (2.24)* 0.001
TC/HDL-C 3.67 (1.39) 4.02 (1.72) 4.59 (2.16)* 0.021
LDL-C/HDL-C 1.81 (0.52) 1.90 (0.90) 1.79 (0.71) 0.051
Non HDL-C 100.9 (33.9) 102.6 (38.3) 107.1 (43.2) 0,575
Apo AI, mg/dL 120.9 (18.0) 113.7 (19.6) 109.1 (21.2)* 0.001
Apo B, mg/dL 62.8 (10.6) 65.2 (15.8) 65.2 (17.5) 0.533
Apo B/Apo AI 0.53 (0.12) 0.60 (0.15) 0.61 (0.16)* 0.003
LDL-C/ApoB 1.38 (0.4) 1.33 (0.48) 1.37 (0.53) 0.810
HDL-C/ApoA 0.35 (0.09) 0.33 (0.12) 0.32 (0.10) 0.122
LDL (−), mg/mL 8.9 (5) 10.8 (4.9) 10.5 (5.2) * 0.042
Anti LDL(−), mg/mL 8.5 (2.6) 7.5 (2.7)* 7.2 (3.0)* 0.010
HDL size, nm 10.8 (2.7) 10.8 (2.3) 10.9 (3.2) 0.638
Glucose, mg/dL 79.3 (12.8) 78.0 (12.5) 82.0 (13.2) 0.130
Insulin, uU/mL 15.3 (7.1) 19.8 (8.2)* 25.9 (14.5)*;** <0.001
HOMA-IR 3.0 (1.5) 3.9 (2.0)* 5.3 (3.1)*;** <0.001
HW, healthy weight; OV, overweight; OB, obese; BMI, Body Mass Index; WC,
waist circumference, HOMA-IR, homeostasis model assessment of insulin
resistance; TC, total cholesterol; LDL, low density lipoprotein; HDL, high
density lipoprotein.
Results were described as mean (standard deviation). *P < 0.05 vs HW group.
**P < 0.05 vs OV group.
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the same way, Rizos et al. [12] and Lagos et al. [36]
observed a high total Lp-PLA2 activity in patients with
metabolic syndrome, however, HDL-Lp-PLA2 showed
low activity. Accordingly, our results confirm the impact
of HDL and LDL on Lp-PLA2 activity given the strong
association of this enzyme with Apo B/Apo AI ratio, that
was the most important parameter related to the risk of
increasing of Lp-PLA2 activity in adolescents.
The negative association of Lp-PLA2 with HDL-size
signals a possible scenario where the functionality of
HDL particles is impaired. Accordingly, Pascot et al.,
[37] showed that the small HDL particle has been
associated with atherogenic dyslipidemic profile and
hyperinsulinemia. More recently, Medina-Urrutia et al.
[38] demonstrated that adolescents with small HDL have
reduced HDL-C, high triglycerides and HOMA-IR. Rizos
et al. [12] verified that patients with metabolic syndrome
have higher Lp-PLA2 than the control group, but the
enzyme linked to HDL-Lp-PLA2 was lower in this group
and negatively associated with HOMA-IR.
Tsimikas et al. [39], analyzing patients with or without
cardiovascular events, observed that Lp-PLA2 was posi-
tively correlated with HOMA-IR in the two groups;
nonetheless, the correlation was higher in the cardio-
vascular event group. In this fashion, our study
demonstrated that this enzyme was positively correlated
with glucose, reinforcing the notion of the negative im-
pact of obesity on glucose metabolism.
Previous studies have shown that Lp-PLA2 is a good
marker for cardiovascular risk in adults [10,15,40]. For
instance, the Lp-PLA2 Studies Collaboration showed
that the enzyme activity was positively correlated with
non-HDL-C, LDL-C, Apo B and negatively correlated
with HDL-C and Apo AI [10]. In the same way, Sabatine
et al. [41] emphasized that Lp-PLA2 is an important pre-
dictor of coronary revascularization and unstable angina,
and can also be treated as a new risk factor.
In contrast to many investigations related to negative
impact of obesity on lipids, few studies including chil-
dren and adolescents that linked obesity, lipid profile
and Lp-PLA2. At the moment, there are only four stud-
ies evaluating Lp-PLA2 in children and adolescents.
First, Okada et al. [42] showed that the Lp-PLA2 con-
centration of 17 obese children (11.9 ± 0.7 years old) was
positively correlated with weight, waist/height ratio,
subscapular/triceps ratio and LDL-C level. Castro et al.
[43] compared diabetic young adults and adolescents
(24.9 ± 7.8 years old) with controls (24.3 ± 9.6 years old),
observing higher Lp-PLA2 activity and elevated suscepti-
bility for oxidized LDL in diabetic patients. Subsequently,
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Figure 1 Lp-PLA2 activity in adolescents according to BMI, tertiles of waist circumference and fat mass percentage. A: Lp-PLA2 activity
stratified by BMI. B: Lp-PLA2 activity stratified by waist circumference tertiles. C: Lp-PLA2 activity stratified by fat mass percentage tertiles.
*P = 0.001 vs HW group or vs Lower tertile. HW, healthy weight; OV, overweight; OB, obese; BMI, Body Mass Index; WC, waist circumference.
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Nagel et al. [44], studying children with 10 years old,
observed that overweight was positively associated with
cardiometabolic markers, including Lp-PLA2 concentra-
tion. In 2011, Motykova et al. [45], examining a group of
non-diabetic obese/overweight children, verified that body
weight reduction determined a drop of Lp-PLA2 levels,
but even after this alteration the concentrations remain
elevated. Our study confirms the negative impact of Lp-
PLA2 and amplifies these results in function of sample
size, number cardiometabolic markers and the age of the
adolescents included.
In addition, many studies have shown that Lp-PLA2
activity is elevated in hypercholesterolemic, diabetic and
metabolic syndrome patients [12,46]. Nambi et al. [47]
associated C-reactive protein and Lp-PLA2 to traditional
risk factors for cardiovascular disease and proposed that
these variables can be especially useful in individuals
that are in intermediate risk according to these eva-
luations. Hence, Lp-PLA2 appears to be an important
link between oxidation, inflammation, and altered lipid
profile and insulin resistance on cardiovascular diseases.
This action maybe involves the formation of lyso-
phosphatidylcholine and isoprostanes that are the bio-
active lipids released by Lp-PLA2 [14].
In spite of the important results obtained, we believe
that this study shows limitations directly related to the
design (cross-sectional) that limits the establishment of
the causal impact of our results on prevalence of clinical
events.
Finally, we conclude that in adolescence, Lp-PLA2
changes in function of obesity, and that it shows impor-
tant associations with markers of cardiovascular risk, in
particular with waist circumference, glucose, HDL size
and Apo B/Apo AI ratio. This supports the hypothesis
that Lp-PLA2 can be a biomarker of cardiovascular risk
Table 4 Multivariable linear regressions between Lp-PLA2
and cardiometabolic factors
Lp-PLA2
R2 P* β
Model 0.263
Apo B/Apo AI 0.000 0.327
HDL size 0.000 −0.326
WC 0.006 0.171
Glucose 0.038 0.119
WC, waist circumference; HDL size; high density lipoprotein size.
Variables in log form.
*Significant level (P < 0.05).
Table 5 Odd Ratio for Lp-PLA2 activity highest quartile
Lp-PLA2
<15.9 ≥15.9 P*
TC, mg/dL 1 Ref 1.012 0.004
LDL-C, mg/dL 1 Ref 1.012 0.003
HDL-C, mg/dL 1 Ref 0.983 0.162
TG, mg/dL 1 Ref 1.004 0.178
HOMA-IR 1 Ref 1.127 0.032
HDL size, nm 1 Ref 0.930 0.245
LDL(−), mg/mL 1 Ref 1.000 0.757
Anti LDL(−), mg/mL 1 Ref 0.878 0.020
Apo AI mg/dL 1 Ref 0.993 0.374
Apo B mg/dL 1 Ref 1.042 0.000
Apo B/Apo AI 1 Ref 73.5 0.000
LDL-C/ApoB 1 Ref 1.265 0.443
HDL-C/ApoAI 1 Ref 0.123 0.168
BMI, kg/m2 1 Ref 1.022 0.340
WC, cm 1 Ref 1.014 0.126
Fat mass,% 1 Ref 1.015 0.379
HW, healthy weight; OV, overweight; OB, obese; BMI, Body Mass Index; WC,
waist circumference, HOMA-IR, homeostasis model assessment of insulin
resistance; TC, total cholesterol, TG, triglycerides; LDL, low density lipoprotein;
HDL, high density lipoprotein.
*Significant level (P < 0.05).
Table 3 Univariated regression model between Lp-PLA2
and cardiometabolic factors
Lp-PLA2
R2 P* β
BMI, kg/m2 0.038 0.003 0.195
WC, cm 0.073 0.000 0.270
Fat mass,% 0.034 0.004 0.186
TC, mg/dL 0.035 0.004 0.186
LDL-C, mg/dL 0.016 0.051 0.128
HDL-C, mg/dL 0.001 0.671 −0.028
TG, mg/dL 0.008 0.163 0.091
TG/HDL-C 0.007 0.199 0.084
LDL-C/HDL-C 0.010 0.121 0.121
TC/HDL-C 0.018 0.042 0.133
Non HDL-C 0.022 0.022 0.149
HDL-C/ApoAI 0.001 0.585 0.036
Apo AI, mg/dL 0.019 0.038 −0.137
Apo B, mg/dL 0.082 0.000 0.293
Apo B/Apo AI 0.118 0.000 0.343
LDL-C/ApoB 0.000 0.775 −0.019
LDL(−), mg/mL 0.001 0.706 0.025
Anti LDL(−), mg/mL 0.013 0.078 −0.115
HDL size , nm 0.085 0.000 −0.291
Insulin, uU/mL 0.039 0.002 0.198
Glucose, mg/dL 0.019 0.034 0.138
HOMA-IR 0.047 0.001 0.216
BMI, Body Mass Index; WC, waist circumference, HOMA-IR, homeostasis model
assessment of insulin resistance; TC, total cholesterol; TG, triglycerides; LDL,
low density lipoprotein; HDL, high density lipoprotein.
Variables in log form, except for percentages. *Significant level (P < 0.05).
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in adolescence, however for confirm this; new prospec-
tive cohorts will be required.
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